Savvy Advisors Inc. Purchases 2,522 Shares of Johnson & Johnson $JNJ

Savvy Advisors Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 12.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 22,214 shares of the company’s stock after acquiring an additional 2,522 shares during the period. Savvy Advisors Inc.’s holdings in Johnson & Johnson were worth $3,393,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Johnson & Johnson by 0.5% in the first quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after acquiring an additional 1,170,120 shares during the last quarter. Northern Trust Corp increased its stake in Johnson & Johnson by 0.4% in the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after acquiring an additional 130,645 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after acquiring an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after acquiring an additional 448,666 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

JNJ opened at $186.39 on Thursday. The stock has a market cap of $449.07 billion, a PE ratio of 17.99, a PEG ratio of 2.20 and a beta of 0.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The business has a 50 day moving average of $182.88 and a 200-day moving average of $167.17. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

A number of research analysts recently commented on JNJ shares. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Loop Capital set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday, October 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Citigroup raised their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.